The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
作者信息
Hooper D C, Wolfson J S
出版信息
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
Abstract
摘要
相似文献
1
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
2
[Fluoroquinolones].
Mikrobiyol Bul. 1987 Apr;21(2):151-7.
3
In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
Infection. 1986 May-Jun;14(3):142-4. doi: 10.1007/BF01643481.
4
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
Eur J Clin Microbiol. 1987 Apr;6(2):179-82. doi: 10.1007/BF02018204.
5
Clinical use of the quinolones.
Lancet. 1987 Dec 5;2(8571):1319-22. doi: 10.1016/s0140-6736(87)91205-0.
6
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Eur J Clin Microbiol. 1986 Apr;5(2):138-40. doi: 10.1007/BF02013968.
7
The adverse effects of fluoroquinolones.
J Antimicrob Chemother. 1987 Jun;19(6):709-11. doi: 10.1093/jac/19.6.709.
8
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 1986 Feb;29(2):374-5. doi: 10.1128/AAC.29.2.374.
9
Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
Scand J Infect Dis. 1986;18(2):149-51. doi: 10.3109/00365548609032321.
10
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
Infection. 1985 Sep-Oct;13(5):219-24. doi: 10.1007/BF01667215.
引用本文的文献
1
Advances in the Synthesis and Biological Applications of Enoxacin-Based Compounds.
Biomolecules. 2024 Nov 7;14(11):1419. doi: 10.3390/biom14111419.
2
Comparative Evaluation of L-PRF and Ofloxacin Incorporated L-PRF as an Adjunctive to SRP-A Split-Mouth Randomized Clinical Trial.
J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1369-S1372. doi: 10.4103/jpbs.jpbs_382_23. Epub 2024 Apr 16.
3
sequence type 410 with carbapenemases: a paradigm shift within toward multidrug resistance.
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0133923. doi: 10.1128/aac.01339-23. Epub 2024 Jan 9.
4
Draft Genome Sequences of 14 Fluoroquinolone-Resistant Escherichia coli Isolates from Imported Shrimp.
Microbiol Resour Announc. 2023 Apr 18;12(4):e0111622. doi: 10.1128/mra.01116-22. Epub 2023 Mar 1.
5
Chemical Aspects of Human and Environmental Overload with Fluorine.
Chem Rev. 2021 Apr 28;121(8):4678-4742. doi: 10.1021/acs.chemrev.0c01263. Epub 2021 Mar 16.
6
Expression of the qepA1 gene is induced under antibiotic exposure.
J Antimicrob Chemother. 2021 May 12;76(6):1433-1440. doi: 10.1093/jac/dkab045.
7
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Viruses. 2020 Dec 23;13(1):8. doi: 10.3390/v13010008.
8
Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli.
J Antimicrob Chemother. 2021 Jan 1;76(1):77-83. doi: 10.1093/jac/dkaa417.
9
Fluorometric determination for ofloxacin by using an aptamer and SYBR Green I.
Mikrochim Acta. 2019 Sep 5;186(10):668. doi: 10.1007/s00604-019-3788-8.
10
Characterizing Shigella species distribution and antimicrobial susceptibility to ciprofloxacin and nalidixic acid in Latin America between 2000-2015.
PLoS One. 2019 Aug 2;14(8):e0220445. doi: 10.1371/journal.pone.0220445. eCollection 2019.
本文引用的文献
1
Urinary tract antiseptics.
Med Clin North Am. 1982 Jan;66(1):199-208. doi: 10.1016/s0025-7125(16)31453-5.
2
Treatment of uncomplicated gonorrhea with rosoxacin.
Antimicrob Agents Chemother. 1981 Nov;20(5):625-9. doi: 10.1128/AAC.20.5.625.
3
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
4
The pharmacokinetics and tissue penetration of ofloxacin.
J Antimicrob Chemother. 1984 Dec;14(6):647-52. doi: 10.1093/jac/14.6.647.
5
Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.
Antimicrob Agents Chemother. 1984 Sep;26(3):289-91. doi: 10.1128/AAC.26.3.289.
6
Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.
J Pharm Sci. 1984 Oct;73(10):1379-82. doi: 10.1002/jps.2600731014.
7
Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
J Antimicrob Chemother. 1984 Sep;14 Suppl C:83-9. doi: 10.1093/jac/14.suppl_c.83.
8
Pharmacokinetics and tissue penetration of enoxacin.
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
9
Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. doi: 10.1128/AAC.25.4.463.
10
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
J Antimicrob Chemother. 1984 Mar;13(3):237-44. doi: 10.1093/jac/13.3.237.
Zotero 插件